Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBT (2018 - 2025)

Historic EBT for Neurogene (NGNE) over the last 5 years, with Q3 2025 value amounting to -$21.1 million.

  • Neurogene's EBT fell 365.48% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.8 million, marking a year-over-year decrease of 2393.35%. This contributed to the annual value of -$75.7 million for FY2024, which is 4376.38% down from last year.
  • Neurogene's EBT amounted to -$21.1 million in Q3 2025, which was down 365.48% from -$23.2 million recorded in Q2 2025.
  • Over the past 5 years, Neurogene's EBT peaked at -$11.9 million during Q2 2023, and registered a low of -$23.2 million during Q2 2025.
  • Its 3-year average for EBT is -$17.8 million, with a median of -$18.6 million in 2024.
  • Per our database at Business Quant, Neurogene's EBT tumbled by 5713.92% in 2024 and then crashed by 365.48% in 2025.
  • Quarter analysis of 3 years shows Neurogene's EBT stood at -$14.0 million in 2023, then plummeted by 40.71% to -$19.7 million in 2024, then dropped by 7.35% to -$21.1 million in 2025.
  • Its EBT was -$21.1 million in Q3 2025, compared to -$23.2 million in Q2 2025 and -$22.8 million in Q1 2025.